Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
50%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

recruiting250%
completed250%

Recent Activity

2 active trials
Showing 4 of 4
completedphase_3

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-C )

NCT06522269
completedphase_2

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-A )

NCT06492239
recruitingphase_3

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-D )

NCT06522282
recruitingphase_2

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-B )

NCT06492265

Clinical Trials (4)

Showing 4 of 4 trials
NCT06522269Phase 3

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-C )

Completed
NCT06492239Phase 2

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-A )

Completed
NCT06522282Phase 3

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-D )

Recruiting
NCT06492265Phase 2

Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-B )

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
4